Plain-English translation of NCT06937788 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Atopic Dermatitis research guide →This trial is comparing two medications— and —to see which one works better for people with severe eczema. Rather than running a brand-new study, researchers are using data already collected from eczema patients at German clinics to answer this question, which makes the results reflect real-world treatment experiences.
Severe eczema causes intense itching, visible skin damage, and serious quality-of-life problems. While both of these medications are approved for eczema, doctors need clear evidence from real patients about which one works better and how it affects not just skin symptoms but also daily life, sleep, and emotional well-being.
You likely qualify if…
You likely don't qualify if…
You do not need to do anything special—this study uses medical information already collected during your routine eczema care at a German clinic. Researchers will access your existing visit notes, skin severity scores, and quality-of-life surveys to compare how well the two medications work. Your participation involves sharing this existing data with the research team.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Germany
Enrollment target
~240 participants
Started
August 2021
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in August 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Thomas Birkner
Center for Evidence-based Healthcare, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.